Introduction In the biopharmaceutical industry, the term "A Mab" (Monoclonal Antibody) has become synonymous with the modern era of targeted therapeutics. With over 100 Mabs approved by the FDA and a global market exceeding $200 billion, these large, complex proteins have revolutionized the treatment of cancers, autoimmune diseases, and infectious diseases. However, the journey from a hybridoma cell line to a commercially viable drug product is a gauntlet of scientific and engineering challenges.
High turbidity in the load causes column fouling and pressure spikes >3 bar. A Mab A Case Study In Bioprocess Development
Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%. 3.2 Viral Inactivation and Neutralization To ensure safety, the eluate undergoes low-pH viral inactivation (pH 3.6 for 90 minutes). For Mab-X, which is moderately acid-labile, the team adds 100 mM sodium acetate as a stabilizing excipient during this step. Post-inactivation, pH is raised to 5.5 using 2M Tris base. Analytical data confirm >4 log reduction of model viruses (xMuLV) without compromising product quality. 3.3 Polishing: Cation Exchange (CEX) and Anion Exchange (AEX) Mab-X requires two polishing steps due to a closely related charge variant (a deamidated isoform at Asn-55). Introduction In the biopharmaceutical industry, the term "A